[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
[ Mon, Jul 08th 2024 ]: WOPRAI
Matthew Biegler Maintained (BPMC) at Buy with Increased Target to $125 on, Jul 8th, 2024
- 🞛 This publication is a summary or evaluation of another publication
Matthew Biegler of Oppenheimer, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $114 to $125 on, Jul 8th, 2024.
Matthew has made no other calls on BPMC in the last 4 months.
There are 11 other peers that have a rating on BPMC. Out of the 11 peers that are also analyzing BPMC, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Berens of "Leerink Partners" Upgraded from Sell to Hold and Increased Target to $97 on, Monday, May 6th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Increased Target to $104 on, Friday, May 3rd, 2024
- Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $75 on, Friday, May 3rd, 2024
These are the ratings of the 8 analyists that currently disagree with Matthew
- Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $130 on, Friday, June 28th, 2024
- Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $125 on, Friday, June 7th, 2024
- Sudan Loganathan of "Stephens & Co." Initiated at Buy and Held Target at $140 on, Tuesday, May 14th, 2024
- Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $168 on, Monday, May 6th, 2024
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $135 on, Friday, May 3rd, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Sell with Increased Target to $76 on, Friday, May 3rd, 2024
- David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $110 on, Friday, April 26th, 2024
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $130 on, Friday, April 26th, 2024